Greenwich LifeSciences, Inc.GLSINASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
0.39%
↓ 99% below average
Average (27q)
73.60%
Historical baseline
Range
High:1432.85%
Low:-89.12%
Volatility
2068.0%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 0.39% |
| Q2 2025 | 34.86% |
| Q1 2025 | -57.76% |
| Q4 2024 | 168.65% |
| Q3 2024 | -0.69% |
| Q2 2024 | 5.17% |
| Q1 2024 | -5.94% |
| Q4 2023 | 8.10% |
| Q3 2023 | 56.44% |
| Q2 2023 | -24.53% |
| Q1 2023 | -25.64% |
| Q4 2022 | 42.62% |
| Q3 2022 | 172.17% |
| Q2 2022 | -61.87% |
| Q1 2022 | -19.53% |
| Q4 2021 | 214.10% |
| Q3 2021 | 18.07% |
| Q2 2021 | 97.37% |
| Q1 2021 | -52.92% |
| Q4 2020 | 278.96% |
| Q3 2020 | 4.79% |
| Q2 2020 | 0.61% |
| Q1 2020 | -42.05% |
| Q4 2019 | -9.08% |
| Q3 2019 | -85.31% |
| Q2 2019 | 1432.85% |
| Q1 2019 | -89.12% |
| Q4 2018 | 0.00% |